ADVENTRX updates ANX-514 candidate for FDA approval ADVENTRX Pharmaceuticals, Inc. Today provided an revise on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.S tadalafil generic . Food and Medication Administration motivated that ANX-514 cannot be approved predicated on the results from the bioequivalence study of ANX-514 and that additional development activities would be required for approval. Culley, Chief Executive Officer of ADVENTRX. Culley continuing. Insight: Research and Practice in Visual Impairment and Blindness provides been the journal’s new title by January 1, 2011. Insight instantly conveys the journal’s content, stated Dr.